Form 4: Halozyme Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Bernadette Connaughton, a Director of Halozyme Therapeutics, Inc., sold 1,626 shares of common stock on August 10, 2026 for $102.80 per share.
Summary
- Open-market sale: disposed of 1,626 Common Stock at $102.80 ($167,153) on August 10, 2026; holds 40,418 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $167,153 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Bernadette Connaughton — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Open-market sale | Common Stock | 1,626 | $103 | $167.2K | 40,418 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Open-market sale (1,626 shares) |
Keywords
insider transaction, Form 4, HALO, HALOZYME THERAPEUTICS, INC., bearish, Bernadette Connaughton
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.